Aberrations in the p53 tumor suppressor pathway are associated with hematological malignancies. p53-dependent cell cycle control, senescence and apoptosis functions are actively involved in maintaining hematopoietic homeostasis under normal and stress conditions. While loss of p53 function promotes leukemia and lymphoma development in humans and mice, increased p53 activity inhibits hematopoietic stem cell function and results in myelodysplasia. Thus, exquisite regulation of p53 activity is critical for homeostasis. Most of our understanding of p53 function in hematopoiesis is derived from genetically engineered mice. Here we summarize some of these models, the various mechanisms that disrupt the regulation of p53 activity, and their relevance to human disease.
Introduction
The tumor suppressor p53 is a ubiquitously expressed transcription factor maintained in an inactive, latent form in most cell types. p53 is stabilized and activated in response to cellular stressors such as DNA damage, hypoxia and oncogene activation 1 . Activated 4 express stem cell antigen 1 (Sca1+) and c-Kit (Kit+, CD117), a transmembrane tyrosine kinase that serves as a receptor for stem cell factor. These HSCs can be identified by flow cytometry as the Lin-Sca1+Kit+ (LSK) population 20, 21 . While LSK defines the basic marker set used to identify the HSCs, additional markers such as CD34, CD38, CD48, CD150, Flt3 are also used in conjunction to further refine HSCs [22] [23] [24] [25] [26] . Some investigators also use rhodamine staining or Hoechst dye efflux side population to identify the stem cell population 26 .
Most of our understanding about p53 regulation and stress response comes from a series of genetically engineered mouse models generated during the past two decades.
In this review, we will discuss models that disrupt the p53 pathway that expand our understanding of p53 mediated stress and tissue-dependent cell fate decisions in hematopoiesis.
p53 deregulation in hematopoietic tumors
p53 regulates a range of physiological functions including ageing, development, cell metabolism, differentiation, fertility, skin pigmentation, stem cell function and tissue homeostasis 27 . Given its pleiotropic activity, it comes as no surprise that disruption of the p53 pathway is a common denominator in many malignancies. Indeed, more than 50%
of human tumors carry a mutation in TP53, and many other tumors carrying wild type TP53 alleles exhibit attenuated p53 activity by various mechanisms 28, 29 . Germline mutations of TP53 cause Li-Fraumeni syndrome (LFS), a genetic disorder characterized by a dramatically increased incidence of many kinds of tumors that include sarcomas, breast cancers, leukemia, and lymphomas 30, 31 . Genetically engineered mice that lack p53 or express a mutant form of p53 (p53R172H, p53R172P, p53R270H) are prone to
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From early onset of tumor development [32] [33] [34] [35] [36] . A high percentage of these tumors are lymphomas, a tumor of hematopoietic T-or B-cell origin [33] [34] [35] [36] . Furthermore, p53 gene dosage impacts tumor latency as mice heterozygous for these mutations develop tumors slightly later than homozygous mutant mice [33] [34] [35] .
Surprisingly, in contrast to solid tumors, hematological malignancies present a rather low incidence of genetic alterations in TP53 (10-20%) 37, 38 . TP53 mutations/deletions have been reported in chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) 39 . Nonetheless, aberrations in TP53 correlate with an inferior clinical outcome in hematological cancers 40, 41 . For instance, in patients with CLL, deletion of the short arm of chromosome 17 (TP53 maps to band 17p13.1), is remarkably predictive of poor outcome with standard chemo-immunotherapeutic regimens 42 . Loss of TP53 also acts as a prognostic marker for acute myeloid leukemia (AML) 43 .
These data suggest that other mechanisms besides mutations could be involved in deregulation of the p53 pathway. Indeed, attenuation of p53 function by increased levels of its inhibitors Mdm2 and Mdm4 results in tumors of hematological origin in mice 44, 45 . In 6
The genomic region at chromosome 1q harboring the p53 negative regulator MDM4
(also known as HDMX) is also amplified in several types of cancer 48 . MDM4 amplifications have been recently described in a high percentage of patients with myeloproliferative neoplasm during their transformation to AML 49 . In this context, 1q
gains (i.e. MDM4 amplifications) are mutually exclusive with TP53 mutations, a phenomenon also observed in solid tumors 50 . Overexpression of MDM4 has also been reported in CLL which responds poorly to the MDM2 inhibitor Nutlin, implicating MDM4
as an important p53 inhibitor in CLL 51 . Altogether these data highlight the importance of dampening p53 levels in transformation of the hematopoietic system.
p53 loss impairs hematopoietic stem cell function
In the hematopoietic system, p53 is primarily expressed in HSCs and regulates their quiescence and self-renewal 52 . This is critical for preserving the lifelong pool of HSCs that sustain the highly regenerative hematopoietic system 52 . Genetically engineered mice that lack p53 have a two-to threefold increase in their HSC pool [52] [53] [54] [55] . This is likely due to the higher rate of cellular proliferation of p53 deficient HSCs 52 . Interestingly though, these highly proliferative p53-deficient HSCs lack the equivalent repopulation capability in comparison to their wild type counterparts (Figure 1 60 . This also correlates with the finding that suppression of p53 function facilitates hematopoietic reconstitution after cytotoxic therapy 61 . Taken together, these data indicate that p53 plays a cytoprotective role in HSCs by preventing their entry into the cell-cycle and maintaining their quiescence.
The role of p53 is not limited to HSCs as p53 also negatively regulates self-renewal in neural 62 and mammary stem cells 63 . Furthermore, depletion of p53 promotes induced pluripotent stem (iPS) cell generation [64] [65] [66] . Concurrent restoration of p53 activity in a mouse model with radiation did not protect against tumor onset, while restoration 8 days post-IR was effective in tumor suppression.
Similarly, conditional deletion of p53 four weeks after IR resulted in lymphoma rates comparable to disrupting p53 prior to IR 79, 80 . These data suggest that p53-activity post-IR is more important for tumor protection.
Overall, p53 response to genotoxic stressors perturbs hematopoiesis by promoting apoptosis and altering the dynamics of HSCs and progenitor cell proliferation.
Constitutive p53 activity impairs hematopoietic homeostasis
Increase in p53 activity above basal levels is detrimental to longterm HSC fitness ( Figure   1 ). p53 activity is characterized by the phosphorylation of amino terminal serine and threonine residues. Transgenic mice in which the p53 phosphorylation sites at threonine-21 and serine-23 are mutated to aspartic acid, a phospho-mimicking amino acid have constitutive p53 activation and exhibit an ageing phenotype that correlates with depletion of adult stem cells in multiple tissues including the bone marrow ( 
Aberrations in p53 regulators have major implications for hematopoiesis
Mouse models show that aberrations in the expression level of Mdm2 and Mdm4 modulate p53 activity and impact the hematopoietic system. Decreased expression of either of these two inhibitors leads to activation of p53 and associated anomalies in the hematopoietic system (Table 1) 70,84 .
Mdm2 is required during primitive erythropoiesis to inhibit p53-mediated apoptosis 86 .
Genetically engineered mice with homozygous deletion of Mdm2 die prematurely at E3.5 due to lethal activation of p53 87, 88 . Recently Evan's group used a novel strategy to bypass this limitation and probed Mdm2 role in p53 regulation during hematopoiesis.
They used a mouse model in which p53 activity could be reversibly toggled between inactive and active stages 89 . Restoration of p53 activity in an Mdm2-null adult mouse led to an almost complete ablation of radio-sensitive tissues that included the bone marrow, thymus, spleen, small intestine, and colon via apoptosis and resulted in lethality.
Consistent with the induction of bone marrow aplasia, analyses of peripheral blood also revealed a dramatic reduction in all hematopoietic lineages. Thus, inhibition of p53 activity by Mdm2 is required for HP viability. 97 . This is likely due to irreversible p53 binding and thus inhibition of p53 activity. We also observe a similar radioresistant phenotype in mice with an Mdm4 allele that lacks the sequence encoding the RING domain necessary for Mdm4-Mdm2 interaction 98 .
RING domain deficient Mdm4ΔRING is more stable than Mdm4 resulting in less p53
activity. Thus, heterozygous Mdm4 +/ΔRING mice survive 6 Gy IR unlike Mdm4 +/− mice and do not die of hematopoietic defects. These data validate the role of Mdm4 in dampening p53 activity during hematopoietic homeostasis and in response to DNA damage.
Mdm4 has also been tested as a therapeutic target for p53 activation 99 . Restoration of p53 in Mdm4 −/− adult tissues induces p53-target genes and causes widespread apoptosis in radiosensitive tissues. Most of the damage is limited to the lymphoid organs and the bone marrow 99 . Interestingly, unlike Mdm2, the p53-dependent pathologies induced in Mdm4-deficient tissues are milder and fully reversible implying that short-term inhibition of Mdm4 for p53 activation could be a more beneficial strategy with less toxicity in hematological malignancies. In summary, loss of p53 function provides radioprotection and promotes HSC proliferation together with an increase in hematological tumors. On the other hand enhanced p53 activity inhibits HSC proliferation and imparts radio-sensitivity (Figure 1 ).
Altogether, these results indicate that p53 plays a critical role in regulating hematopoietic cell functions under both normal and stressed conditions.
Role of p53 downstream targets in hematopoiesis
p53-target genes involved in both apoptotic (e.g. Puma) and cell cycle arrest (e.g. p21)
pathways are significantly induced in the bone marrow after IR (Figure 2 ). The role of p53 target pro-apoptotic genes Puma and Bax in modulating the function of hematopoietic stem and progenitor cells in response to high-dose irradiation is already established [100] [101] [102] . Mice lacking either of these genes do not exhibit radiation induced lethality (Table 1) . In fact, deletion of Puma or Bax rescues the lethality caused by p53
hyper-activity in sensitive mouse models 81, 102 . HSCs from Puma-null mice are highly quiescent and along with the progenitor cells are also more efficient in DNA-damage repair 100, 101 . This provides further evidence in support of dominant role of apoptotic genes in hematopoietic degeneration. In agreement, mice with compromised p53 apoptotic activity (p53R172P retain activation of cell cycle genes) do not undergo HP failure after DNA damage (V.Pant unpublished observations). These data suggest that inhibition of p53 apoptotic activity or down modulation of specific targets could be used as a potential strategy to protect HSCs from the cytotoxic and myelosuppressive effects of radio/chemotherapy.
Still unclear is the role of p21 mediated cell cycle arrest in response to radiation. In a mixed strain background, loss of p21 affected hematopoietic recovery after IR as the HSC pool was completely depleted due to uncontrolled cell cycling, leading to lethality (Table 1) 103 . However, in the C57Bl/6 background, no such fatality or HSC exhaustion was observed 104 . In our hands, we also did not observe an increased radio-susceptibility in p21 null mice on a C57Bl/6 background after 6 Gy IR (V.Pant unpublished observations). Also, it was recently shown that deletion of a single p21 allele could partially rescue the radio-lethality of p53-7KR mice after 6 Gy IR 82 . p53-7KR mice display a differential transcriptional activity with higher induction of p21 in the bone marrow over apoptotic genes. These data further emphasize that under certain conditions p21 contributes to hematopoietic sensitivity by controlling transition through the G1/S boundary. However, as mentioned above, blocking apoptosis completely rescues the HSC defects in wild type and p53 hyperactive mice, supporting it as the predominant pathway involved.
Studies are ongoing to identify p53 downstream targets which are specifically involved in maintaining HSC quiescence. Gfi-1 (growth factor independent-1) and Other targets modulated by p53 during differentiation of HSCs remain to be identified.
p53
515C/515C mice as a model for apoptosis independent activities of p53 in hematopoiesis Previously, our lab has generated a knock-in mouse (p53
515C
) that expresses a mutant form of p53 protein, p53R172P that is defective for apoptosis but retains partial cell cycle arrest and senescence functions 32 . Homozygousity of the p53 515C allele partially rescues the early embryonic lethality of Mdm2-null mice 110 . Mdm2 −/− p53 515C/515C mice are born at expected Mendelian ratio with normal cellularity of all major hematopoietic organs at birth. However, soon after, these organs undergo progressive degradation which culminates in complete arrest of hematopoiesis. By day P10-14, the spleens and thymi lose all lymphoid cells and the bone marrow becomes completely aplastic resulting in death of these young pups. These observations indicate that in the absence of Mdm2, increase in p53R172P activity causes rapid and progressive loss of hematopoietic stem and progenitor cells post-partum. These results are in congruence with a report that p53 is maintained at low levels during embryonic development but increases a few days after birth 111 . Overall, these data highlight the importance of p53-dependent cell cycle arrest in hematopoiesis.
For
To gain further insights into the mechanism causing the HP defect, we investigated the stress signals that instigate increase in p53 levels and activity during pre-and post-natal development 112 . We detected higher ROS levels in the bone marrow of post-natal pups with N-Acetyl Cysteine (NAC) in vivo rescued the hematopoietic defect.
These data uphold the pro-oxidant role of p53 under stress conditions, perhaps as a possible signal to stabilize p53, in contrast to its antioxidant role in non-stress conditions (Figure 2 ) 59 . Stress due to the absence of Mdm2 induces ROS and stabilizes/activates p53R172P leading to an increase in cell cycle arrest and senescence functions 112 . This is further corroborated by elevated mRNA levels of p53 targets p21 and Dcr2 and an independent senescence marker p15 in the BM cells 114 . Furthermore, Senescence
Associated-βgal activity, is also higher in the post-natal BMs. The hematopoietic defect in these mice is HSC specific as bone marrow cells from these mice fail to rescue lethally irradiated wild type mice in BM transplantation assays. Importantly, these defects are p53-dependent.
Extrapolation of these data implicate Mdm2 as a critical regulator of p53 activity in hematopoietic tissues when ROS levels increase. This regulation is critical for stem cell survival and differentiation. The increased ROS levels observed in patients with myeloid malignancies 115 may also be p53-dependent. As such, antioxidant treatment could be a therapeutic strategy for these patients. Furthermore, the data also show that in addition 
TP53 in ribosomopathies: Diamond Blackfan anemia and 5q syndrome
Ribosomal stress resulting from impaired nascent ribosome biogenesis or defects in ribosome function is another mechanism by which the p53 pathway is activated and commonly associates with the hematopoietic phenotype observed in a number of bone marrow failure syndromes 116 . Ribosomal proteins function primarily as structural components of the 40S and 60S ribosomal subunits. Mutations in individual ribosomal proteins disrupt the assembly of the protein into the ribosomal subunits [117] [118] [119] [120] [121] . As a result, unengaged ribosomal proteins remain free to bind and block Mdm2, leading to p53 accumulation and activation of a cell cycle arrest response in the erythroid lineage [122] [123] [124] .
This ultimately results in an erythroid failure phenotype that characterizes several genetic syndromes such as Diamond-Blackfan anemia (DBA) 117, 125 . DBA is an autosomal dominant syndrome characterized by aplasia of the erythroid lineage which is associated with growth retardation and limb, cardiac and craniofacial malformations with a very wide range of severity in all its phenotypic manifestations 126 . Patients with DBA exhibit severe macrocytic anemia with reticulocytopenia and aplasia of red blood cell precursors in the context of an otherwise normocellular bone marrow 127 . The absence of red blood cell precursors is due to impaired proliferation and increased apoptosis at the erythrocyte burst-forming unit stage. Knockdown of RPS19 (the ribosomal protein most frequently involved in DBA) in mouse fetal liver cells induces increased levels of p53 and p21 with decreased proliferation and delay of the G1/S phase of the cell cycle 128 . A similar erythroid phenotype in RPS19-deficient zebrafish is alleviated upon suppression of p53 129 . In human bone marrow derived CD34+ cells in which the expression of RPS19 or RPS14 is downmodulated, the subsequent erythroid phenotype is completely rescued upon treatment with the p53 inhibitor pifithrin-α. Conversely, nutlin-3, a compound that activates p53 through inhibition of Mdm2, selectively impairs erythropoiesis 130 A mouse model in which coordinate deletion of loci syntenic with the common deleted region of the 5q− syndrome (including RPS14 haploinsufficiency), recapitulates the erythroid phenotype characteristic of 5q-syndrome 138 . Intercrossing this mouse with p53-deficient mice completely rescues the progenitor cell defect, restoring all hematopoietic bone marrow populations, again implicating a p53-dependent mechanism in the pathophysiology of this disorder induced by RPS14 alterations 138 . Thus, increased p53 activity caused by ribosomal dysfunction is critical in the evolution of myelodysplatic syndromes again emphasizing the need to squelch p53 activity. The availability of mouse models which recapitulate human disease further our mechanistic insight into disease manifestation and provide a unique opportunity to test strategies targeting p53 activity in a preclinical setting. However, mouse models do have their own set of limitations. Most of the models used in lab carry a germline deletion/mutation of p53 pathway component which differs from the subtle somatic mutations observed in human tumors. The genetic background of mouse models also influences the tumor spectrum. Differences in the mouse and human stroma could affect the tumor initiation, progression and treatment profiles. Moreover, the common strategy of using whole body radiation response for testing the fitness of the hematopoietic system presents a scenario unlikely ever to be recapitulated in human patients.
Perspectives
Nonetheless, the benefits of using these models to test hypotheses far outweigh the negatives.
Summary
Mouse models with alterations in the p53 pathway have been invaluable in shedding light as to the role of p53 in hematopoiesis. During steady state, basal p53 activity regulates HSC quiescence and self-renewal. Lack of p53 activity promotes HSC proliferation which eventually leads to accumulation of DNA damage and tumor development. Excessive p53 activation on the other hand, adversely affects cellularity of key organs and promotes loss of hematopoietic progenitors. Therefore, fine-tuned regulation of p53 activity is critical to maintain homeostasis and recovery after tissue damage, particularly in tissues with high cellular turnover such as the bone marrow. A better understanding of the p53 regulatory mechanisms is critical to harness p53 activity for therapeutic purposes in cancer and other diseases. 
